For in vitro diagnostic use. Others Elecsys sFlt-1 and Elecsys PlGF IVD Elecsys® sFlt-1 and Elecsys® PlGF PID00001096 sFlt-1/PIGF ratio for preeclampsia 09 015 353 160 9 015 353 160 09015353160 9015353160 09015353160 sFLT1 Elecsys cobas e 100 V2 Elecsys sFlt-1 07613336230671 Reagents, kits 100 tests cobas e 411/601/602 true 09 015 418 160 9 015 418 160 09015418160 9015418160 09015418160 PLGF Elecsys cobas e 100 V2 Elecsys PlGF 07613336230756 Reagents, kits 100 tests cobas e 411/601/602 true 09015353501 Elecsys sFlt-1 and Elecsys PIGF sFlt-1/PIGF ratio for preeclampsia en 1 FF0000000783DE0E FF0000000781B10E 09015353160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassays for the in vitro quantitative determination of the soluble fms‑like tyrosine kinase‑1/placental growth factor (sFlt‑1/PlGF) ratio in human serum. The sFlt‑1/PlGF ratio is indicated as an aid in the risk assessment of pregnant women, with a singleton pregnancy (23+0 to 34+6/7 weeks’ gestation) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), to develop preeclampsia with severe features within 2 weeks from testing. The sFlt‑1/PlGF ratio should be used in conjunction with clinical assessment and routine laboratory testing. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09015418501 Elecsys sFlt-1 and Elecsys PIGF sFlt-1/PIGF ratio for preeclampsia en 1 FF0000000783E00E FF00000007825C0E 09015418160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassays for the in vitro quantitative determination of the soluble fms‑like tyrosine kinase‑1/placental growth factor (sFlt‑1/PlGF) ratio in human serum. The sFlt‑1/PlGF ratio is indicated as an aid in the risk assessment of pregnant women, with a singleton pregnancy (23+0 to 34+6/7 weeks’ gestation) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), to develop preeclampsia with severe features within 2 weeks from testing. The sFlt‑1/PlGF ratio should be used in conjunction with clinical assessment and routine laboratory testing. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

User Profile

Select your user profile

Elecsys^® sFlt-1 and Elecsys^® PlGF

Overview

Ordering Information

Technical Documents

Access important product documentation including relevant certificates and other resources.

Compatible Instruments

Related products

Contact us